LivaNova PLC (NASDAQ:LIVN) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of LivaNova PLC (NASDAQ:LIVN) have been given an average recommendation of “Moderate Buy” by the eight research firms that are presently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and five have issued a buy rating on the company. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $59.7143.

LIVN has been the topic of a number of research reports. Barclays upped their price objective on LivaNova from $55.00 to $58.00 and gave the company an “equal weight” rating in a report on Thursday, August 21st. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of LivaNova in a research note on Saturday, September 27th. The Goldman Sachs Group set a $55.00 price objective on shares of LivaNova and gave the stock a “neutral” rating in a research report on Wednesday. Needham & Company LLC restated a “buy” rating and set a $64.00 price objective on shares of LivaNova in a research report on Wednesday, September 3rd. Finally, Wall Street Zen upgraded LivaNova from a “buy” rating to a “strong-buy” rating in a research note on Saturday, August 9th.

Institutional Investors Weigh In On LivaNova

Several hedge funds have recently modified their holdings of the company. Invesco Ltd. grew its position in LivaNova by 714.7% during the 2nd quarter. Invesco Ltd. now owns 1,028,713 shares of the company’s stock worth $46,313,000 after acquiring an additional 902,447 shares during the last quarter. AQR Capital Management LLC raised its position in LivaNova by 111.7% in the first quarter. AQR Capital Management LLC now owns 1,571,295 shares of the company’s stock valued at $60,809,000 after purchasing an additional 829,115 shares during the last quarter. Scopia Capital Management LP acquired a new stake in shares of LivaNova during the second quarter valued at about $36,657,000. Nuveen LLC bought a new stake in shares of LivaNova during the first quarter worth about $30,954,000. Finally, Artisan Partners Limited Partnership grew its holdings in shares of LivaNova by 112.9% during the second quarter. Artisan Partners Limited Partnership now owns 1,247,609 shares of the company’s stock worth $56,167,000 after purchasing an additional 661,480 shares during the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

LivaNova Stock Performance

Shares of LIVN stock opened at $53.37 on Monday. LivaNova has a 52 week low of $32.48 and a 52 week high of $58.91. The company has a market capitalization of $2.91 billion, a price-to-earnings ratio of -13.72 and a beta of 0.95. The company has a 50-day simple moving average of $52.66 and a 200 day simple moving average of $45.44. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.09 and a current ratio of 1.29.

LivaNova (NASDAQ:LIVN) last issued its quarterly earnings data on Wednesday, August 6th. The company reported $1.05 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.84 by $0.21. The firm had revenue of $352.50 million during the quarter, compared to the consensus estimate of $332.20 million. LivaNova had a negative net margin of 16.13% and a positive return on equity of 14.57%. The business’s revenue for the quarter was up 10.6% compared to the same quarter last year. During the same period last year, the business posted $0.93 earnings per share. On average, sell-side analysts predict that LivaNova will post 2.85 earnings per share for the current year.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.